NeoMatrix Personalized Cancer Vaccine Program at EIT Health Final in Paris, 2-3 December 2019
Takis among the 7 European Finalists at EIT Health Summit
Paris, 2 December, 2019 – Takis, an Italian Biotech Company leader in Gene Therapy, Cancer Vaccines and generation of monoclonal antibodies is proud to announce its participation at the
the place where collective ideas transform the future of healthcare.
Takis S.R.L. will present NeoMatrix, a neoantigen-based cancer vaccine, as a proof-of-concept of personalized immunology. NeoMatrix starts from tumor biopsy and gets to the manufacturing of a personalized cancer vaccine in 5 weeks.
“We are proud to have been selected among the finalists in this important European competition. Not only as Takis Biotech, but also as the only Italian company among incredible companies with brilliant ideas and teams able to create new opportunities for patients” said Luigi Aurisicchio, CEO/CSO.
“We know that immune system has a key role in fighting cancer” said Dr. Fabio Palombo, Leader and Champion of NeoMatrix. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide precision therapies to human patients able to complement current standard of care.”
Stay tuned for the competition!
For more information please see our NeoMatrix web page
Check out all EHC finalists at: FINALISTS EHC 2019